Anika Therapeutics Inc. revenue for the last year amounted to 166.66 M USD, the most of which — 101.93 M USD — came from its highest performing source at the moment, Ostoarthritis Pain Management, the year earlier bringing 97.89 M USD. The greatest contribution to the revenue figure was made by United States — last year it brought Anika Therapeutics Inc. 123.13 M USD, and the year before that — 119.15 M USD.